Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Small cell lung cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,319 result(s) found for: Small cell lung cancer. Displaying page 8 of 66.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2007-006033-14 Sponsor Protocol Number: Version10 Start Date*: 2008-03-13
    Sponsor Name:University Hospital Lund, Thoracic Oncology Unit, Dept of Respiratory Medicine
    Full Title: A randomized phase III study of standard treatment +/- enoxaparin in small cell lung cancer.
    Medical condition: Patients with small cell lung cancer, who are going to receive chemotherapy treatment with a platinum- and topoisomeras inhibitor containing regimen.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10041067 Small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-020229-42 Sponsor Protocol Number: ML21869 Start Date*: 2010-07-18
    Sponsor Name:ROCHE
    Full Title: A randomized phase II trial of erlotinib (TARCEVA) or intermittent dosing of erlotinib and docetaxel in male former smokers with locally advanced or metastatic squamous nonsmall cell lung cancer...
    Medical condition: Non-small cell lung cancer (NSCLC), locally advanced (stage IIIB), metastatic (stage IV) or recurrent.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 PT
    9.1 10029522 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003415-31 Sponsor Protocol Number: ARD12166 Start Date*: 2012-01-25
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: Randomized Phase II Study of Cabazitaxel versus Topotecan in Small Cell Lung Cancer Patients with Progressive Disease during or after a First Line Platinum Based Chemotherapy
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041071 Small cell lung cancer stage unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) GR (Completed) NO (Completed) IT (Completed) DE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002029-12 Sponsor Protocol Number: ETOP10-16 Start Date*: 2017-04-24
    Sponsor Name:ETOP IBCSG Partners Foundation
    Full Title: A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with confirmed EGFRm and T790M
    Medical condition: Patients with locally advanced or metastatic (stage IIIb-IVb) EGFRm (exon 19 deletion or exon 21 L858R) NSCLC with T790M resistance mutation at progression on prior EGFR TKI therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Ongoing) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000280-81 Sponsor Protocol Number: GO40290 Start Date*: 2018-07-04
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF MTIG7192A, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC N...
    Medical condition: Locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004698-29 Sponsor Protocol Number: TH-CR-415 Start Date*: 2014-05-12
    Sponsor Name:Threshold Pharmaceuticals, Inc.
    Full Title: A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination with TH-302 vs. Pemetrexed in Combination with Placebo as Second-line Chemotherapy for...
    Medical condition: Advanced Non-Squamous, Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IT (Completed) DE (Prematurely Ended) CZ (Completed) GR (Prematurely Ended) ES (Temporarily Halted) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-013838-25 Sponsor Protocol Number: IMCLCP11-0806 Start Date*: 2009-10-21
    Sponsor Name:ImClone LLC
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of...
    Medical condition: Advanced squamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) HU (Completed) PT (Completed) ES (Ongoing) GR (Ongoing) SK (Completed) IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-022021-15 Sponsor Protocol Number: 2010-022021-15 Start Date*: 2011-02-16
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III, SUPERIORITY TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ACETYL-L-CARNITINE IN COMBINATION WITH A ...
    Medical condition: Patients with histologically documented, locally advanced (stage IIIB with either pleural effusion or supra-clavicular nodal disease) or metastatic (stage IV) or recurred after an adjuvant treatmen...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 LLT
    9.1 10029521 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001903-42 Sponsor Protocol Number: IPH5201-201 Start Date*: 2023-03-07
    Sponsor Name:Innate Pharma SA
    Full Title: A Phase II Multicenter, open label, non-randomized study of neoadjuvant and Adjuvant Treatment with IPH5201 and durvalumab in patients with resectable, early-Stage (II to IIIA) Non-Small Cell Lung ...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006359-11 Sponsor Protocol Number: BO20571 Start Date*: 2007-09-14
    Sponsor Name:F. Hoffmann-La Roche
    Full Title: A Phase II study of Tarceva® in Combination with Avastin® versus chemotherapy plus Avastin® in 1st line advanced NSCLC patients
    Medical condition: Advanced Non-Small-Cell-Lung-Cancer (Stage IIIb and IV) 1st line
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) NL (Completed) ES (Completed) LT (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017591-24 Sponsor Protocol Number: H8Z-MC-JACW Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 2 Study of LY2181308 in Combination with Docetaxel versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who Were Previously Treated with Fi...
    Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000612-30 Sponsor Protocol Number: D910MC00001 Start Date*: 2021-03-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curat...
    Medical condition: Completely resected stage II-III NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BG (Completed) BE (Completed) FR (Completed) GR (Completed) HU (Completed) CZ (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003512-27 Sponsor Protocol Number: AIO-YMO/TRK-0120 Start Date*: 2021-12-08
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study
    Medical condition: Patients with EGFR-mutation positive NSCLC The target population will comprise 3 parallel cohorts, for each of which a minimum of 10 subjects is planned to be enrolled: 1. Irradiation of bone, sol...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025064 Lung carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007096 Cancer of lung LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001123-35 Sponsor Protocol Number: IDI-ONC-2-20070220 Start Date*: 2007-11-18
    Sponsor Name:ISTITUTO DERMOPATICO IMMACOLATA
    Full Title: PHASE II STUDY OF DOCETAXEL AND OXALIPLATIN ASSOCIATION AS I LINE THERAPY IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS: SCHEDULE-DEPENDENT ACTIVITY AND MOLECULAR TARGETS EVALUATION
    Medical condition: NON SMALL CELL LUNG CANCER (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004959-30 Sponsor Protocol Number: 1373.3 Start Date*: 2016-02-25
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised, double-blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in patients with...
    Medical condition: Non small cell lung cancer stage III after concurrent chemoradiation therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NO (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002485-19 Sponsor Protocol Number: 08061 Start Date*: 2008-11-21
    Sponsor Name:EORTC-European Organisation for Research and Treatment of Cancer
    Full Title: Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a "sensitive" relapse
    Medical condition: Patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse (extensive or limited disease).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041067 Small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002555-17 Sponsor Protocol Number: ESR-15-11650 Start Date*: 2017-01-09
    Sponsor Name:AZIENDA OSPEDALIERO - UNIVERSITARIA "POLICLINICO - VITTORIO EMANUELE"
    Full Title: OSIRIS (OSImertinib Rechallenge TKI In Subsequent line of therapy) A Phase II, Noncomparative, Open label, Multicentre, Study of AZD9291, in Patients with Locally Advanced or Metastatic EGFR mutate...
    Medical condition: Locally Advanced or Metastatic EGFR mutated, "T790M undetectable or unknown" Non Small Cell Lung Cancer (Stage IIIB-IV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003298-28 Sponsor Protocol Number: M06-822 Start Date*: 2007-05-23
    Sponsor Name:Abbott Laboratories Limited (Queenborough, Kent, ME11 5EL, England)
    Full Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies.
    Medical condition: Small cell lung carcinoma (SCLC) (North America or UK) and other non-hematological malignancies (North America only).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041067 Small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003039-65 Sponsor Protocol Number: P30-120 Start Date*: 2008-06-03
    Sponsor Name:Alfacell Corporation
    Full Title: A phase I / II trial of intravenous Onconase(R) in subjects with non-small cell lung cancer
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004170-15 Sponsor Protocol Number: UCL/12/2015 Start Date*: 2016-11-17
    Sponsor Name:University College London
    Full Title: A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine versus carboplatin/etoposide therapy alone in small cell lung cancer (SCLC)
    Medical condition: Small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:58:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA